SEC 13F Intelligence

Managers / Q1 2020 · view latest →

Consonance Capital Management LP

CIK 0001544773 · 1370 AVENUE OF THE AMERICAS, SUITE 3301, NEW YORK, NY, 10019 · 212.660-8062

Reported Value
$1.3B
Q1 2020
Positions
31
Filings on Record
15
2019–present window
Filed
May 15, 2020
original filing

Summary

Consonance Capital Management LP reported $1.3B in U.S.-listed holdings across 31 positions for Q1 2020.

Its largest position, Karyopharm Therapeutics, represents 10.3% of the portfolio.

Compared with Q4 2019, the fund opened 8 new positions and exited 12.

Portfolio Metrics

Turnover
+28.9%
vs prior filed quarter
Top-10 Concentration
+61.6%
share of reported value
Largest Position
+10.3%
Karyopharm Therapeutics
New / Exited
8 / 12
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q1 ’19: $1.6BQ1 ’19Q2 ’19: $1.4BQ3 ’19: $1.0BQ3 ’19Q4 ’19: $1.6BQ1 ’20: $1.3BQ1 ’20Q2 ’20: $1.7BQ3 ’20: $821MQ3 ’20Q4 ’20: $1.1BQ1 ’21: $938MQ1 ’21Q2 ’21: $831MQ3 ’21: $183MQ3 ’21Q4 ’21: $153MQ1 ’22: $59MQ1 ’22Q2 ’22: $24MQ3 ’22: $7MQ3 ’22filingsflow.com

Portfolio Composition

By security type
Common Stock: 88.2%Other: 11.8%
  • Common Stock · 88.2% · $1.2B
  • Other · 11.8% · $159M

Quarter-over-Quarter Changes full breakdown →

vs Q4 2019 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
AKBAAKEBIA THERAPEUTICS INCNEW+7.12M7.12M+$54M$54M
PRNBPRINCIPIA BIOPHARMA INCNEW+689.7K689.7K+$41M$41M
CYTKCYTOKINETICS INCNEW+3.43M3.43M+$40M$40M
KINIKSA PHARMACEUTICALS LTDNEW+2.24M2.24M+$35M$35M
CHRSCOHERUS BIOSCIENCES INCNEW+2.02M2.02M+$33M$33M
XENEXENON PHARMACEUTICALS INCNEW+1.98M1.98M+$22M$22M
BLUBELLUS HEALTH INC NEWNEW+1.60M1.60M+$16M$16M
AXOVANT GENE THERAPIES LTDNEW+3.65M3.65M+$9M$9M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q1 2020

31 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1KARYOPHARM THERAPEUTICS INCCOM10.27%$138M7.18M
2UTHRUNITED THERAPEUTICS CORP DELhistory →COM9.53%$128M1.35M
3AUPHAURINIA PHARMACEUTICALS INChistory →COM7.47%$100M6.91M
4CHEMOCENTRYX INCCOM6.87%$92M2.30M
5SRPTSAREPTA THERAPEUTICS INChistory →COM6.00%$81M823.2K
6KDMNKADMON HLDGS INChistory →COM4.87%$65M15.61M
7OMEROMEROS CORPhistory →COM4.46%$60M4.48M
8CDNACAREDX INChistory →COM4.33%$58M2.66M
9AKBAAKEBIA THERAPEUTICS INChistory →COM4.02%$54M7.12M
10EPIZYME INCCOM3.82%$51M3.30M
11QUREUNIQURE NVhistory →SHS3.65%$49M1.03M
12ASSEMBLY BIOSCIENCES INCCOM3.51%$47M3.18M
13PRNBPRINCIPIA BIOPHARMA INChistory →COM3.05%$41M689.7K
14CYTKCYTOKINETICS INChistory →COM NEW3.01%$40M3.43M
15AXGNAXOGEN INChistory →COM2.76%$37M3.57M
16KINIKSA PHARMACEUTICALS LTDCOM CL A2.58%$35M2.24M
17APTOSE BIOSCIENCES INCCOM NEW2.56%$34M5.80M
18RETROPHIN INCCOM2.51%$34M2.31M
19CHRSCOHERUS BIOSCIENCES INChistory →COM2.44%$33M2.02M
20KRYSKRYSTAL BIOTECH INChistory →COM2.11%$28M654.6K
21INTRA CELLULAR THERAPIES INCCOM1.89%$25M1.65M
22XENEXENON PHARMACEUTICALS INChistory →COM1.67%$22M1.98M
23LIMINAL BIOSCIENCES INCCOM1.64%$22M3.29M
24BLUBELLUS HEALTH INC NEWhistory →COM NEW1.19%$16M1.60M
25OXFORD IMMUNOTEC GLOBAL PLCORD SHS0.86%$12M1.24M
26IVERIC BIO INCCOM0.81%$11M3.15M
27ADMAADMA BIOLOGICS INCCOM0.73%$10M3.38M
28AXOVANT GENE THERAPIES LTDCOM0.66%$9M3.65M
29OVIDOVID THERAPEUTICS INCCOM0.57%$8M2.58M
30BIOTELEMETRY INCCOM0.14%$2M49.2K
31APELLIS PHARMACEUTICALS INCCOM0.02%$268,00010.0K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q3 2022$7M2Nov 14, 202213F-HRchanges · EDGAR ↗
Q2 2022$24M7Aug 15, 202213F-HRchanges · EDGAR ↗
Q1 2022$59M8May 16, 202213F-HRchanges · EDGAR ↗
Q4 2021$153M15Feb 14, 202213F-HRchanges · EDGAR ↗
Q3 2021$183M17Nov 15, 202113F-HRchanges · EDGAR ↗
Q2 2021$831M32Aug 16, 202113F-HRchanges · EDGAR ↗
Q1 2021$938M35May 17, 202113F-HRchanges · EDGAR ↗
Q4 2020$1.1B38Feb 16, 202113F-HRchanges · EDGAR ↗
Q3 2020$821M27Nov 16, 202013F-HRchanges · EDGAR ↗
Q2 2020$1.7B32Aug 14, 202013F-HRchanges · EDGAR ↗
Q1 2020$1.3B31May 15, 202013F-HRchanges · EDGAR ↗
Q4 2019$1.6B35Feb 14, 202013F-HRchanges · EDGAR ↗
Q3 2019$1.0B30Nov 14, 201913F-HRchanges · EDGAR ↗
Q2 2019$1.4B30Aug 14, 201913F-HRchanges · EDGAR ↗
Q1 2019$1.6B26May 15, 201913F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.